...
首页> 外文期刊>ChemMedChem >Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains
【24h】

Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains

机译:Rafoxanide和Closantel通过在其C末端域上与高度保守的变构位点结合来抑制Spak和OSR1激酶

获取原文
获取原文并翻译 | 示例

摘要

SPAK and OSR1 are two protein kinases that have emerged as attractive targets in the discovery of novel antihypertensive agents due to their role in regulating electrolyte balance in vivo. Herein we report the identification of an allosteric pocket on the highly conserved C-terminal domains of these two kinases, which influences their activity. We also show that some known WNK signaling inhibitors bind to this allosteric site. Using in silico screening, we identified the antiparasitic agent rafoxanide as a novel allosteric inhibitor of SPAK and OSR1. Collectively, this work will facilitate the rational design of novel SPAK and OSR1 kinase inhibitors that could be useful antihypertensive agents.
机译:Spak和OSR1是两种蛋白激酶,其由于它们在体内调节电解质平衡方面的作用而被出现在新的抗高血压药物中具有吸引力的靶标。 在此,我们报告了这两个激酶的高度保守的C末端结构域上的颠覆袋的鉴定,这会影响它们的活性。 我们还表明一些已知的WNK信号传导抑制剂与该变构位点结合。 在Silico筛选中,我们将抗披炎剂醛昔单抗作为氨基克和OSR1的新型变构抑制剂鉴定为抗寄生虫剂。 共同努力,这项工作将促进新的氨基达和OSR1激酶抑制剂的合理设计,这可能是有用的抗高血压药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号